BioSpace News Archive

Royal Philips, a global leader in health technology, announced physicians will now have access to advanced new 3D image guidance capabilities through its Image-Guided Therapy Mobile C-arm System – Zenition, delivering enhanced clinical accuracy and efficiency, and aiming to improve the outcomes for patients undergoing endovascular treatment.

ADC Therapeutics SA announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications in Japan.

Azafaros B.V. announced its participation at the 18th Annual WORLDSymposium™, a research conference dedicated to lysosomal storage diseases, taking place from February 7 – 11, 2022, in San Diego, CA.

PhenoVista Biosciences announced that it has secured funding from BroadOak Capital Partners, a life science-focused investor.

Syneos Health ® today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors.

Merck Allocates 3 Million Courses of Molnupiravir to be Provided in First Half of 2022 for Use in Low- and Middle-Income Countries.

Osmotica Pharmaceuticals plc announced today that Brian Markison, Chief Executive Officer and James “JD” Schaub, Chief Operating Officer, will host a video webcast to discuss recent UPNEEQ® trends, pending expansion into the medical aesthetics market and other general business updates.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its recently approved product, vasopressin, an A-rated generic alternative to Vasostrict with 180 days of marketing exclusivity.

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced that it has initiated a program to develop monoclonal antibodies to treat schizophrenia and other chronic mental illnesses.

Krystal Biotech, Inc. announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors.